CALCA and pulmonary fibrosis: developed a clodronate liposomal and fibroblast‐derived exosomal hybrid drug nanocarrier, where the clodronate can deplete the KC via passive targeting and the homing properties of homologous exosome favor pulmonary fibrosis‐specific accumulation and penetration.[128] The nanocarrier significantly enhanced the delivery of nintedanib, an antifibrotic agent approved for treating pulmonary fibrosis, to pulmonary fibrotic lesions and achieved a remarkable improvement in treating pulmonary fibrosis.